ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1490

Effects of Biologic Drugs on Prognosis of Rheumatoid Arthritis Among Patients with Poor Glycated Hemoglobic A1c (HbA1c) Control

Yusuke Miwa1 and Tsuyoshi Kasama2, 1Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Shinagawa-ku Tokyo, Japan, 2Div of Rheumatology, Showa University School of Med, Shinagawa-ku Tokyo, Japan

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Biologic agents and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Monday, October 22, 2018

Session Title: Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster II: Diagnosis and Prognosis

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:

Poor control of glycated hemoglobic A1c (HbA1c) worsens prognosis for diabetes mellitus and various complicated diseases. Corticosteroids exacerbate poor HbA1c control. This study, investigated the effects of biological disease-modifying antirheumatic drugs (bDMARDs) on HbA1c control among patients with RA, as it has not been examined before.

Methods: In total, 632 patients with RA from the All Showa University of RA database (ASHURA) was used for our study. The following background factors were investigated: age; gender,; type of bDMARD; dosage of methotrexate and prednisolone (PSL); usage of conventional synthetic DMARD and nonsteroidal anti-inflammatory drugs; body mass index; smoking history; HbA1c; presence or absence of hypertension and dyslipidemia; and levels of serum creatinine, C reactive protein, and matrix metalloproteinase-3. We also used the simplified disease activity index (SDAI) and health assessment questionnaire (HAQ) to evaluate RA disease activity and activities of daily living, respectively. Poor HbA1c control was defined as HbA1c 6.0; accordingly, we divided the patients into good and poor HbA1c control groups. Primary and secondary failures, adverse drug events, missing data, and patients who moved or had care withdrawn were excluded. SDAI and PSL dosage were the primary and secondary endpoints, respectively. Repeated measures analysis of variance (ANOVA) evaluated the HAQ scores before treatment and 1 year later.

Results:

Of 632 patients, 296 patients enrolled in this study. The SDAI was from 27.7 ± 15.6 to 7.1 ± 8.0 in the poor HbA1c control group (n = 83) and from 22.9 ± 14.0 to 6.3 ± 7.6 in the good HbA1c control group (n = 213). There was no interaction between the groups. Repeated measures ANOVA showed a significant difference between the groups (p = 0.011) and during the treatment period (p = 0.001). PSL dosage was from 3.5 ± 3.6 (mg/day) to 2.2 ± 3.0 in the poor HbA1c control group and from 2.3 ± 3.0 to 1.6 ± 3.6 in the good HbA1c control group. A significant difference was observed between the groups (p = 0.007) and during the treatment period (p = 0.001). Notably, there was no significant difference in HAQ. No patient reported HbA1c increasing by 1.0 or more during 1 year.

Conclusion:

Results showed that bDMARD therapy reduced RA disease activity and PSL dosage in both groups. Therefore, we recommend bDMARD treatment for RA regardless of good or poor HbA1c control


Disclosure: Y. Miwa, Astellas Pharma Inc., 2,Mitsubishi Tanabe Pharma Corporation, 2,AbbVie CK, 2,Pfizer Japan Inc., 2,Chugai Pharmaceutical Co., Ltd., 2,Ono Pharmaceutical Co., Ltd., 2; T. Kasama, None.

To cite this abstract in AMA style:

Miwa Y, Kasama T. Effects of Biologic Drugs on Prognosis of Rheumatoid Arthritis Among Patients with Poor Glycated Hemoglobic A1c (HbA1c) Control [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 10). https://acrabstracts.org/abstract/effects-of-biologic-drugs-on-prognosis-of-rheumatoid-arthritis-among-patients-with-poor-glycated-hemoglobic-a1c-hba1c-control/. Accessed January 17, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/effects-of-biologic-drugs-on-prognosis-of-rheumatoid-arthritis-among-patients-with-poor-glycated-hemoglobic-a1c-hba1c-control/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.